- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00940017
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
5. januar 2010 opdateret af: Pfizer
A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects
The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
24
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06102
- Pfizer Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Healthy adult subjects willing to comply with the study requirement.
Exclusion Criteria:
- Clinical significant disease.
- Sensitive to study medication.
- Not willing to comply with the study requirement.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: 1
|
Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Plasma Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
Tidsramme: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Cmax = maximum observed plasma concentration; measured in micrograms per milliliter (ug/mL).
Observed directly from the data.
Collected on Day 3.
|
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Plasma PK: Time to Reach Maximum Plasma Concentration (Tmax)
Tidsramme: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Tmax = time (hours) to maximum plasma concentration (Cmax).
Observed directly from data as time of first occurrence.
Collected on Day 3.
|
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Plasma PK: Area Under the Curve From Time Zero to Time = Tau (AUCtau)
Tidsramme: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole; measured as micrograms times hours per milliliter (ug*hr/mL).
Collected on Day 3.
|
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Plasma PK: Plasma Elimination Half-life (t1/2)
Tidsramme: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Collected on Day 3.
|
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Plasma PK: Total Clearance (CL Total)
Tidsramme: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
CL total = total clearance calculated as dose divided by AUCt; measured as milliliters per minute (mL/min).
Collected on Day 3.
|
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Plasma PK: Volume of Distribution at Steady-state (Vss)
Tidsramme: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Vss = volume of distribution at steady-state; measured as liters (L).
Calculated as (CL multiplied by mean residence time extrapolated to infinity [MRTinf]).
MRTinf = [(AUMCt plus t (AUCinf minus AUCt)) divided by AUCt] minus (infusion time divided by 2); AUMCt = area under the first moment curve from time zero to time t; AUCinf = area under the plasma concentration-time curve extrapolated to infinity.
|
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
|
Epithelial Lining Fluid (ELF) PK: Cmax
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
Cmax=maximum observed plasma concentration.
ELF collected by bronchoscopy and bronchoalveolar lavage (BAL) Day 3; determined from BAL sample using urea dilution method: [Drug ELF]=[Drug BAL] multiplied by [Urea SERUM] divided by [Urea BAL].
Drug ELF=anidulafungin or voriconazole (drug) concentration in ELF corrected for dilution; Drug BAL=assayed drug concentration in BAL; Urea SERUM and Urea BAL simultaneously collected.
Summary parameters derived using average data for all subjects; associated to a single subject for reporting purposes (mean with standard deviation not calculated).
|
4, 8, 12, 24 hours after start of infusion
|
ELF PK: Tmax
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
Tmax = time (hours) to maximum plasma concentration (Cmax).
Observed directly from data as time of first occurrence.
ELF collected by bronchoscopy and BAL on Day 3.
|
4, 8, 12, 24 hours after start of infusion
|
ELF PK: AUCtau
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole.
ELF collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
|
4, 8, 12, 24 hours after start of infusion
|
ELF PK: t1/2
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
ELF collected by bronchoscopy and BAL on Day 3.
|
4, 8, 12, 24 hours after start of infusion
|
Alveolar Macrophages (AM): Cmax
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
Cmax = maximum observed plasma concentration; observed directly from the data.
AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
|
4, 8, 12, 24 hours after start of infusion
|
AM: Tmax
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
Tmax = time (hours) to maximum plasma concentration (Cmax).
Observed directly from data as time of first occurrence.
AM collected by bronchoscopy and BAL on Day 3.
|
4, 8, 12, 24 hours after start of infusion
|
AM: AUCtau
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole.
AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
|
4, 8, 12, 24 hours after start of infusion
|
AM: t1/2
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
t1/2 = terminal elimination half-life in hours; Loge(2)Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
AM collected by bronchoscopy and BAL on Day 3.
|
4, 8, 12, 24 hours after start of infusion
|
Overall Drug Penetration Ratio in ELF
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
ELF collected by bronchoscopy and BAL on Day 3. ELF to plasma penetration ratio calculated by dividing area under the plasma concentration-time profile (AUC) in ELF by AUC in plasma from 20 subjects where t is 24 hours for anidulafungin and 12 hours for voriconazole.
Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).
|
4, 8, 12, 24 hours after start of infusion
|
Concentration Ratio in ELF to Plasma
Tidsramme: 4, 8, 12, 24 hours after start of infusion
|
Concentration ratio in ELF to plasma determined by a point estimate within each subject at the time-point where ELF data was available.
|
4, 8, 12, 24 hours after start of infusion
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. september 2008
Primær færdiggørelse (Faktiske)
1. oktober 2008
Studieafslutning (Faktiske)
1. oktober 2008
Datoer for studieregistrering
Først indsendt
13. juli 2009
Først indsendt, der opfyldte QC-kriterier
14. juli 2009
Først opslået (Skøn)
15. juli 2009
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
9. februar 2010
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
5. januar 2010
Sidst verificeret
1. januar 2010
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Infektioner
- Systemisk inflammatorisk responssyndrom
- Betændelse
- Bakterielle infektioner og mykoser
- Sepsis
- Mykoser
- Invasive svampeinfektioner
- Fungemia
- Candidiasis
- Candidiasis, invasiv
- Candidæmi
- Aspergillose
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Enzymhæmmere
- Hormoner, hormonsubstitutter og hormonantagonister
- Cytokrom P-450 CYP3A-hæmmere
- Cytokrom P-450 enzymhæmmere
- Hormonantagonister
- Antifungale midler
- Steroidsyntesehæmmere
- 14-alfa-demethylasehæmmere
- Anidulafungin
- Voriconazol
Andre undersøgelses-id-numre
- A8851020
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Candidæmi
-
Taipei Medical University WanFang HospitalAfsluttetIkke-albicans CandidemiaTaiwan
-
Centre Hospitalier Universitaire DijonUkendt
Kliniske forsøg med anidulafungin and voriconazole
-
PfizerAfsluttetAspergilloseForenede Stater, Australien, Canada, Grækenland, Belgien, Tyskland, Korea, Republikken, Polen, Den Russiske Føderation, Spanien, Kalkun, Thailand, Brasilien, Tjekkiet, Frankrig, Indien, Italien, Holland, Peru, Portugal, Singapore, ... og mere
-
PfizerAfsluttetCandidiasisForenede Stater, Korea, Republikken
-
National Cancer Institute (NCI)AfsluttetUspecificeret fast tumor i barndommen, protokolspecifik | Neutropeni | InfektionForenede Stater
-
Radboud University Medical CenterAfsluttetLeukæmi | Leukæmi, Myeloid, Akut | Myelodysplastisk syndromHolland
-
Radboud University Medical CenterAfsluttet
-
Daren K. HeylandPfizer; Queen's University; The Physicians' Services Incorporated FoundationAfsluttetVentilator Associated Pneumonia | LuftvejsinfektionCanada
-
PfizerAfsluttetCandidiasis | Fungemia | NeutropeniPolen, Den Russiske Føderation, Frankrig, Bosnien-Hercegovina, Italien, Slovakiet
-
PfizerVicuron PharmaceuticalsAfsluttet
-
PfizerVicuron PharmaceuticalsAfsluttet
-
Universidade Federal do Rio de JaneiroAfsluttet